Sectors
WVE
Wave Life Sciences, Inc.
4.90
2 x 4.27
2 x 7.50
bid
ask
-
0.14
2.78%
2 @ 04:18 PM
4.93 +0.03 (0.61%)
| Ytd | -71.18% | |
| 1y | -48.96% |
4.84
day range
5.07
4.84
52 week range
21.73
| Open | 5.06 | Prev Close | 5.04 | Low | 4.84 | High | 5.07 | Mkt Cap | 965.54M |
| Vol | 3.80M | Avg Vol | 3.08M | EPS | -1.08 | P/E | N/A | Forward P/E | -4.33 |
| Beta | -1.29 | Short Ratio | 5.75 | Inst. Own | 85.60% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 5.74 | 200-d Avg | 9.36 | 1yr Est | 19.06 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-09 | 2026-09 | -0.33 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | -0.3 | -0.34 | -0.04 | -13.43% |
| 2026-04-28 | 2026-03 | -0.34 | -0.13 | 0.21 | 61.76% |
| 2026-02-26 | 2025-12 | -0.28 | -0.3 | -0.02 | -7.14% |
| 2025-11-10 | 2025-09 | -0.3 | -0.32 | -0.02 | -6.67% |
| 2025-07-30 | 2025-06 | -0.29 | -0.31 | -0.02 | -6.90% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-04 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-07-31 | Citigroup | Upgrade | Buy | Buy |
| 2026-07-31 | B. Riley Securities | Upgrade | Buy | Buy |
| 2026-07-31 | Wedbush | Upgrade | Outperform | Outperform |
| 2026-05-20 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-05-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-08 | BOLNO PAUL B. M.D. | Chief Executive Officer | 275.52K | Sale |
| 2025-12-07 | CORRIGAN MARK | Director | 28.82K | Sale |
| 2026-02-25 | FRANCIS CHRISTOPHER JOHN | Officer | 61.87K | Conversion of Exercise of derivative security |
| 2025-12-10 | GSK PLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-02-08 | MORAN KYLE | Chief Financial Officer | 134.39K | Sale |
| 2026-03-29 | RA CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Kennedy Capital Management, LLC | 429.12K | 2.21M | 0.00% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 4.11M | 21.21M | 2.09% |
| 2026-06-29 | iShares Trust-iShares Russell 2000 ETF | 3.60M | 18.57M | 1.83% |
| 2026-03-30 | T. Rowe Price New Horizons Fund, Inc. | 2.29M | 11.80M | 1.16% |
| 2026-03-30 | T. Rowe Price Health Sciences Fund, Inc. | 2.11M | 10.87M | 1.07% |
| 2026-06-29 | Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.66M | 8.56M | 0.84% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.61M | 8.31M | 0.82% |